The global pathology services market is projected to grow from $212.8 billion in 2024 to $307.9 billion by 2030 at a 6.5% CAGR, driven by rising cancer incidence, digital pathology adoption, and molecular diagnostics expansion. North America leads with 41.2% market share, while AI-enabled platforms are delivering measurable ROI through cost savings and improved efficiency. Large reference laboratory operators are best positioned to capture outsourcing opportunities and scale molecular testing capabilities.

The global blood-based biomarkers market is projected to grow from USD 8.5 billion in 2025 to USD 18.5 billion by 2034, driven by increasing demand for non-invasive diagnostics, rising chronic disease prevalence, and advances in genomics and liquid biopsy technologies. North America leads with 44% market share, while Asia-Pacific shows fastest growth. Key players include Roche, Abbott, Siemens Healthineers, and Thermo Fisher Scientific.

The global animal testing and non-animal alternative testing market reached $15.19 billion in 2025 and is projected to grow to $23.01 billion by 2035 at a CAGR of 4-4.5%. While animal testing dominated with 80.1% market share in 2025, non-animal alternative testing is expected to grow faster at 6.3% CAGR through 2030, driven by advances in organ-on-chip, organoids, AI biosimulation, and genomics. The pharmaceutical industry led end-user applications with 50.1% market share, while North America was the largest regional market at 38.6% of global revenue.

Testie Health, a consumer health company founded by Thea Rose, has launched nationwide with a direct-to-lab STI testing model that allows customers to purchase testing panels online and visit nearby laboratories for sample collection without scheduling a doctor's appointment. The service aims to destigmatize routine STI testing and make it a normal part of preventive healthcare, with results delivered within 48 hours and licensed provider support available for positive results.

Labcorp CEO Adam Schechter sold 4,669 shares worth approximately $1.5 million on August 11, 2026, through a pre-scheduled Rule 10b5-1 trading plan. The sale represents only 4% of his direct holdings, leaving him with 102,565 shares valued at $33 million. The transaction is characterized as routine portfolio management rather than a sign of concern, as the company continues to demonstrate strong financial performance with 6.4% year-over-year revenue growth and 25% operating profit growth.

The global cancer biomarkers market is projected to grow from $25.9 billion in 2026 to $37.8 billion by 2035, with a CAGR of 4.3%. Growth is driven by rising cancer incidence, personalized medicine adoption, advances in NGS and liquid biopsy technologies, and increased biomarker-driven diagnostics. HER2 testing leads by biomarker type (21.1% share), while breast cancer testing dominates by indication (25.1% share). North America captures 52.1% of global market revenue.

Onconetix Inc. (NASDAQ:ONCO) shares surged 23.65% to $0.38 in after-hours trading on Monday, reversing an 18.26% regular session decline. The biotech company reported clinical validation progress for Proclarix, a blood test for prostate cancer detection, with new peer-reviewed publications and initiation of a U.S. validation trial with Labcorp. However, the stock has dropped 99.11% over the past 12 months and currently trades at its annual low.

Labcorp Holdings (LH) shares rose 1.46% after reporting strong Q1 results with adjusted EPS of $4.25 beating consensus of $4.09, and sales of $3.54 billion exceeding expectations. The company raised full-year 2026 adjusted EPS guidance to $18.03 at midpoint, driven by momentum in Diagnostics and Central Laboratory businesses, along with investments in AI and robotics technologies.

The drug development services market is projected to grow from $28.09 billion in 2025 to $50.26 billion by 2030 at a CAGR of 12.4%, driven by increased R&D investments, AI adoption, personalized medicine, and emerging market expansion. Key growth areas include preclinical research, regulatory optimization, and cloud-based data management, with precision medicine and genomics advancements playing pivotal roles.

Labcorp Holdings Inc. (NYSE:LH) announced that its Board of Directors has declared a cash dividend of $0.72 per share of common stock, payable on June 11, 2026, to stockholders of record as of May 29, 2026.

The global drug screening market is projected to reach USD 20.86 billion by 2031, growing at a CAGR of 16.16%. Chromatography and mass spectrometry technologies dominated with 44.77% market share in 2025. Asia-Pacific is the fastest-growing region, driven by expanding healthcare infrastructure and workplace safety initiatives. Market growth is fueled by increasing adoption across workplaces, healthcare settings, and law enforcement, alongside technological advancements in point-of-care testing and rapid detection devices.

The global genomics services market is expected to grow from USD 7.94 billion in 2025 to USD 25.18 billion by 2035, with a CAGR of 11.8%. Growth is driven by increasing genetic disorder prevalence, government-funded precision medicine initiatives, and rising adoption of NGS-based diagnostics. The U.S. market alone is projected to reach USD 10.04 billion by 2035. Next-generation sequencing dominates with 38.42% market share, while Asia Pacific shows the fastest growth at 13.84% CAGR.